Besides the elevated antitumor immune signatures, ARID1A-mutated GI cancers exhibited significantly higher PD-L1 expression levels than ARID1A-wildtype GI cancers that would enhance the immunotherapy response and accordingly result in a better survival prognosis in this cancer subtype. The gene discussed is CD274; the disease is cancer.